THE PURE-PLAY DERMATOLOGY CATEGORY LEADER
Since our foundation in 1981, Galderma has been dedicated to the human body’s largest organ: the skin. We are recognized for our innovative, science-based portfolio of premium flagship brands and services spanning the full spectrum of the fast-growing dermatology market.
A year of growth: building on our momentum
In 2024, we solidified our category leadership by further expanding our broad portfolio, global reach and leading engagement across the full market spectrum. We reached major milestones in our growth journey across all segments.
2024 HIGHLIGHTS:
Presented results from the phase III READY-3 clinical trial
demonstrating the positive efficacy and long duration of RelabotulinumtoxinA in treating frown lines and crow’s feet at the TOXINS International Conference
Cetaphil® took to the runway at New York Fashion Week
with the ‘Face of Cetaphil’ activation and launched the American football-inspired #GameTimeGlow campaign
Launched NEXT by Galderma™
a ground-breaking trend report that unveils the six key trends set to shape the future of aesthetics
Debuted as a publicly-listed company (GALD) on the SIX Swiss Exchange
marking a turning point in our growth journey. Our initial public offering (IPO) marked the largest placement volume in Switzerland since 2017
Relfydess™ received regulatory approval in Europe
for the treatment of frown lines and crow’s feet
Nemluvio® received regulatory approval in the U.S.
for the treatment of adults with prurigo nodularis and for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis. Following approval, Nemluvio® (nemolizumab) was administered in the first patient within two days
Launched our video series Beauty × Medicine
where our CEO Flemming Ørnskov, M.D., MPH led discussions with key dermatology experts
Published the full results from the phase III OLYMPIA 1 trial in JAMA Dermatology
evaluating the efficacy and safety of nemolizumab in adults with moderate-to-severe prurigo nodularis, showing the trial met all primary and key secondary endpoints
GROWTH: EXECUTING OUR STRATEGY TO DRIVE PERFORMANCE
With a proven track record of sustainable value creation, we are building on our solid growth momentum. We continue to deliver a strong performance across categories and geographies through successful execution of our unique Integrated Dermatology Strategy. Going forward, we remain committed to building on the synergies within our company and across our products and services.
Learn more about our growth
INNOVATION: ADVANCING THE SCIENCE OF DERMATOLOGY
At Galderma, we leverage our scientific expertise and in-house R&D platform to remain at the forefront of dermatological innovation. We partner with other leaders in our field to target unmet patient needs and advance dermatology for every skin story.
Learn more about our innovation
BRANDS: OUR SYNERGISTIC, PREMIUM PORTFOLIO
Galderma advances dermatology for every skin story by maintaining and developing a synergistic portfolio of premium flagship brands. Through clinical research, strong partnerships and strategic execution, we drive our company’s growth and expand the options available to patients and consumers all over the world.
Learn more about our brands
Injectable Aesthetics: market-leading neuromodulators
Galderma is committed to delivering the broadest Injectable Aesthetics portfolio on the market, enabling patients and healthcare professionals to achieve personalized results. Neuromodulators are a key component of our offer, including Relfydess™, Alluzience® and Dysport®.
Unmatched Hyaluronic Acid (HA) injectables and biostimulators
To meet the growing global demand for aesthetic treatments, Galderma continuously expands our offerings in HA injectables and biostimulators. We continue to identify and develop new applications for our blockbuster brands, Restylane® and Sculptra®, on the basis of their clinically proven formulas.
Dermatological Skincare: our heritage and a pillar of future growth
Our consumer-facing Dermatological Skincare business is our historical foundation, the origin of our premium portfolio. Our flagship brands are Cetaphil®, which first exceeded 1 billion USD in annual sales in 2023, and Alastin®, which continues to grow in the U.S. and other markets.
Therapeutic Dermatology: expanding treatment options for unmet needs
Galderma is dedicated to improving quality of life for those living with chronic and debilitating skin conditions. We target areas of high patient need such as acne, atopic dermatitis (AD) and prurigo nodularis (PN).
EDUCATION AND SERVICES: OUR PARTNERSHIPS WITH HEALTHCARE PROFESSIONALS
Galderma’s commitment to education and collaboration with healthcare professionals drives innovation and responsible business practices. We strive to positively impact the field by providing our network with leading educational tools and partnership opportunities.
Learn more about our partnerships
10,000+
training events hosted via the Galderma Aesthetics Injector Network (GAIN) in 2024
225,000+
healthcare professionals engaged with in 2024
DELIVERING ON OUR ESG PRIORITIES
Galderma believes Environmental, Social and Governance (ESG) is rooted in every dimension of our business, starting with our purpose of advancing dermatology for every skin story, all the way to actually addressing our patients’ and consumers’ needs. Our fit-for-purpose ESG set-up has focused on building a coherent, pragmatic and value-adding ESG function at Galderma, embedding ESG principles through objectives into every relevant function of the organization.
Discover the full report on non-financial matters
We strive to make a positive impact
4 out of 4
Plants using 100% renewable electricity
>10%
reduction of water intensity in our operations year-on-year
250+
major health approvals since 2020
50%
of our affiliates have received Great Place to Work© cetifications
